Holen Sie sich die Stockscreener-App
105.44
1.47%
1.53
Handel nachbörslich:
105.45
0.01
+0.01%
Schlusskurs vom Vortag:
$103.91
Offen:
$104.99
24-Stunden-Volumen:
245.79K
Relative Volume:
0.36
Marktkapitalisierung:
$5.41B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-16.15
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
+2.80%
1M Leistung:
-4.24%
6M Leistung:
+21.97%
1J Leistung:
+31.45%
1-Tages-Spanne:
$103.96
$106.63
1-Wochen-Bereich:
$102.26
$106.63
52-Wochen-Spanne:
$72.21
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
105.44 | 5.41B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock Sells 7,500 Shares - MarketBeat
Axsome therapeutics’ general counsel sells $2.28 million in stock - Investing.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven? - Yahoo Finance
Axsome Therapeutics to Present SYMBRAVO® Clinical Data at the 67th Annual Scientific Meeting of the American Headache Society - Nasdaq
Prosperity Wealth Management Inc. Buys New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
SYMBRAVO Breakthrough: New Data Reveals Effectiveness in CGRP-Resistant Migraine Patients - Stock Titan
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $172.33 Average Target Price from Analysts - MarketBeat
Axsome Therapeutics (AXSM) Supports Migraine Awareness and Commu - GuruFocus
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders - The Manila Times
Axsome Therapeutics Partners With Migraine Association to Help 40 Million US Patients Find Better Days - Stock Titan
GAMMA Investing LLC Purchases 21,986 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Q3 EPS Forecast for Axsome Therapeutics Decreased by Analyst - MarketBeat
Royal Bank of Canada Has Lowered Expectations for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome initiated with an Outperform at Oppenheimer on revenue boost - MSN
Rhumbline Advisers Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome fell after FDA refuses to review AXS-14 application - MSN
Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC Wainwright - MarketBeat
Equities Analysts Issue Forecasts for AXSM FY2026 Earnings - MarketBeat
Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market By Investing.com - Investing.com Nigeria
Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com
Assenagon Asset Management S.A. Purchases 623,717 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Mark L. Jacobson Sells 25,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
RBC Capital Adjusts Price Target for AXSM, Maintains Outperform - GuruFocus
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Pallas Capital Advisors LLC - MarketBeat
Needham & Company LLC Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00 - MarketBeat
Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital - GuruFocus
Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley - MSN
RBC Capital Adjusts Price Target for AXSM, Maintains Outperform Rating | AXSM Stock News - GuruFocus
Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital | AXSM Stock News - GuruFocus
RBC Lowers Price Target on Axsome Therapeutics to $186 From $193, Keeps Outperform Rating - MarketScreener
Axsome Presents Positive Phase 3 Data for AXS-12 in Narcolepsy at SLEEP 2025 - HCPLive
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OSCR, AXSM and ET - ACCESS Newswire
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Axsome Therapeutics Highlights Seven Presentations on AXS-12 and Solriamfetol at SLEEP 2025 Conference - Nasdaq
Axsome Unveils Phase 3 Narcolepsy Trial Results Among 7 Major Presentations at SLEEP 2025 - Stock Titan
Transcript : Axsome Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener
Axsome Therapeutics, Inc. Announces Availability of Symbravo (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine with or Without Aura in Adults - marketscreener.com
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - simplywall.st
Axsome Therapeutics Launches SYMBRAVO for Migraine Relief - TipRanks
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $185 From $190, Maintains Buy Rating - marketscreener.com
Axsome Therapeutics (AXSM) Launches SYMBRAVO for Migraine Relief in the U.S. | AXSM Stock News - GuruFocus
Revolutionary Migraine Drug SYMBRAVO Now Available: Fast-Acting Relief Targets Multiple Pain Pathways - Stock Titan
Axsome Therapeutics (NASDAQ:AXSM) Given New $150.00 Price Target at Needham & Company LLC - Defense World
Axsome Therapeutics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Canada
Axsome’s fibromyalgia drug application hits FDA roadblock By Investing.com - Investing.com South Africa
Axsome Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AXSM - Benzinga
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Option Exercise |
29.91 |
6,014 |
179,879 |
6,014 |
| Murdock Hunter R. | General Counsel |
Jun 20 '25 |
Sale |
102.47 |
7,500 |
768,525 |
0 |
| Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Sale |
100.12 |
6,014 |
602,122 |
0 |
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):